Technology Insight: utility of TNF-α-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities (original) (raw)
Creech O Jr et al. (1958) Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg148: 616–632 PubMedPubMed Central Google Scholar
Benckhuijsen C et al. (1988) Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics. Eur J Surg Oncol14: 157–63 CASPubMed Google Scholar
Thompson JF and Gianoutsos MP (1992) Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World J Surg16: 227–233 CASPubMed Google Scholar
Wieberdink K et al. (1982) Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol18: 905–910 CASPubMed Google Scholar
Stotter AT et al. (1990) The influence of local recurrence of extremity soft tissue sarcoma on metastasis and survival. Cancer65: 1119–1129 CASPubMed Google Scholar
Gustafson P et al. (1991) Is local recurrence of minor importance for metastases in soft tissue sarcoma? Cancer67: 2083–2086 CASPubMed Google Scholar
Rosenberg SA et al. (1982) The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg196: 305–315 CASPubMedPubMed Central Google Scholar
Williard WC et al. (1992) Comparison of amputation with limb-sparing operations for adult soft tissue sarcoma of the extremity. Ann Surg215: 269–275 CASPubMedPubMed Central Google Scholar
Meric F et al. (2002) Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomas. Cancer95: 1120–1126 PubMed Google Scholar
O'Sullivan B et al. (2002) Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet359: 2235–2241 PubMed Google Scholar
Pisters PW et al. (2002) Preoperative chemoradiation treatment strategies for localized sarcoma. Ann Surg Oncol9: 535–542 PubMed Google Scholar
DeLaney TF et al. (2003) Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. Int J Radiat Oncol Biol Phys56: 1117–1127 PubMed Google Scholar
Pommier RF et al. (1988) Pharmacokinetics, toxicity, and short-term results of cisplatin hyperthermic isolated limb perfusion for soft tissue sarcoma and melanoma of the extremities. Am J Surg155: 667–671 CASPubMed Google Scholar
Klaase JM et al. (1989) Results of regional isolation perfusion with cytostatics in patients with soft tissue tumors of the extremities. Cancer64: 616–621 CASPubMed Google Scholar
Rossi CR et al. (1994) Phase II study on neoadjuvant hyperthermic-antiblastic perfusion with doxorubicin in patients with intermediate or high grade limb sarcomas. Cancer73: 2140–2146 CASPubMed Google Scholar
Feig BW et al. (2004) A prospective evaluation of isolated limb perfusion with doxorubicin in patients with unresectable extremity sarcomas. Ann Surg Oncol11: S80 Google Scholar
Lienard D et al. (1992) High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol10: 50–62 Google Scholar
Eggermont AM et al. (1996) Isolated limb perfusion with high-dose tumor necrosis factor-α in combination with interferon-γ and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol14: 2653–2665 CASPubMed Google Scholar
Eggermont AM and Kirkwood JM (2004) Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer40: 1825–1836 CASPubMed Google Scholar
Lejeune FJ et al. (1993) Regional therapy of melanoma. Eur J Cancer29A: 606–612 CASPubMed Google Scholar
Fraker DL et al. (1996) Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. J Clin Oncol14: 479–89 CASPubMed Google Scholar
Eggermont AM et al. (1993) Treatment of irresectable soft tissue sarcomas of the limbs by isolation perfusion with high dose TNF-α in combination with γ-interferon and melphalan. In Tumor Necrosis Factor: Molecular and Cellular Biology and Clinical Relevance, 239–243 (Eds Fiers W and Buurman WA) Basel: Karger Google Scholar
Eggermont AM et al. (1996) Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas: the cumulative multicenter European experience. Ann Surg224: 756–764 CASPubMedPubMed Central Google Scholar
Eggermont AM et al. (1999) Limb salvage by isolation limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced extremity soft tissue sarcomas: results of 270 perfusions in 246 patients. Proc Am Soc Clin Oncol11: 497
Santinami M et al. (1996) Treatment of recurrent sarcoma of the extremities by isolated perfusion using tumor necrosis factor alpha and melphalan. Tumori82: 579–584 CASPubMed Google Scholar
Gutman M et al. (1997) High dose tumor necrosis factor-α and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation. Cancer79: 1129–1137 CASPubMed Google Scholar
Olieman AF et al. (1998) Feasibility and efficacy of external beam radiotherapy after hyperthermic isolated limb perfusion with TNF-α and melphalan for limb-saving treatment in locally advanced extremity soft-tissue sarcoma. Int J Radiat Oncol Biol Phys40: 807–814 CASPubMed Google Scholar
Olieman AF et al. (1998) Hyperthermic isolated limb perfusion with tumour necrosis factor-α and melphalan as palliative limb-saving treatment in patients with locally advanced soft-tissue sarcomas of the extremities with regional or distant metastases: is it worthwhile? Arch Orthop Trauma Surg118: 70–74 CASPubMed Google Scholar
Rossi CR et al. (1999) Soft tissue limb sarcomas: Italian clinical trials with hyperthermic antiblastic perfusion. Cancer86: 1742–1749 CASPubMed Google Scholar
Lev-Chelouche D et al. (1999) Multifocal soft tissue sarcoma: limb salvage following hyperthermic isolated limb perfusion with high-dose tumor necrosis factor and melphalan. J Surg Oncol70: 185–189 CASPubMed Google Scholar
Lev-Chelouche D et al. (1999) Limb desmoid tumors: a possible role for isolated limb perfusion with tumor necrosis factor-α and melphalan. Surgery126: 963–967 CASPubMed Google Scholar
Lev-Chelouche D et al. (1999) Isolated limb perfusion with high-dose tumor necrosis factor alpha and melphalan for Kaposi sarcoma. Arch Surg134: 177–180 CASPubMed Google Scholar
Lejeune FJ et al. (2000) Limb salvage by neoadjuvant isolated perfusion with TNFα and melphalan for non-resectable soft tissue sarcoma of the extremities. Eur J Surg Oncol26: 669–678 CASPubMed Google Scholar
Hohenberger P et al. (2001) Functional outcome after preoperative isolated limb perfusion with rhTNFα/melphalan for high-grade extremity sarcoma. Eur J Cancer37: S34–S35 Google Scholar
Lans TE et al. (2002) Isolated limb perfusion with tumor necrosis factor and melphalan for nonresectable Stewart-Treves lymphangiosarcoma. Ann Surg Oncol9: 1004–1009 CASPubMed Google Scholar
Noorda EM et al. (2003) Isolated limb perfusion with tumor necrosis factor-α and melphalan for irresectable soft tissue sarcoma of the extremities. Cancer98: 1483–1490 CASPubMed Google Scholar
van Etten B et al. (2003) Fifty tumor necrosis factor-based isolated limb perfusions for limb salvage in patients older than 75 years with limb-threatening soft tissue sarcomas and other extremity tumors. Ann Surg Oncol27: 32–37 Google Scholar
Grünhagen DJ et al. (2005) Isolated limb perfusion with tumor necrosis factor and melphalan prevents amputation in patients with multiple sarcomas in arm or leg. Ann Surg Oncol12: 473–479 PubMed Google Scholar
Lans TE et al. (2005) Isolated limb perfusions with tumor necrosis factor and melphalan for locally recurrent soft tissue sarcoma in previously irradiated limbs. Ann Surg Oncol12: 406–411 CASPubMed Google Scholar
Grünhagen DJ et al. (2006) The palliative value of tumor necrosis factor alpha-based isolated limb perfusion in patients with metastatic sarcoma and melanoma. Cancer106: 156–162 PubMed Google Scholar
Grünhagen DJ et al. (2005) TNF-based isolated limb perfusion for unresectable extremity desmoid tumors. Eur J Surg Oncol31: 912–916 PubMed Google Scholar
Rossi CR et al. (2005) Hyperthermic isolated perfusion with low-dose tumor necrosis factor alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcomas. Ann Surg Oncol12: 398–405 PubMed Google Scholar
Grünhagen DJ et al.: Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-α and melphalan for limb-threatening soft tissue sarcoma. Cancer, in press
Bonvalot S et al. (2005) Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-α be better? Ann Oncol16: 1061–1068 CASPubMed Google Scholar
Grünhagen DJ et al. (2005) TNF dose reduction in isolated limb perfusion. Eur J Surg Oncol31: 1011–1019 PubMed Google Scholar
Hill S et al. (1993) Low dose tumor necrosis factor-α and melphalan in hyperthermic isolated limb perfusion. Br J Surg80: 995–997 CASPubMed Google Scholar
de Wilt JH et al. (1999) Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats. Br J Cancer80: 161–166 CASPubMed Google Scholar
Vrouenraets BC et al. (1999) Absence of severe systemic toxicity after leakage controlled isolated limb perfusion with tumor necrosis factor-α and melphalan. Ann Surg Oncol6: 405–412 CASPubMed Google Scholar
Stam TC et al. (2000) Systemic toxicity and cytokine/acute phase protein levels in patients after isolated limb perfusion with tumor necrosis factor-α complicated by high leakage Ann Surg Oncol7: 268–275 CASPubMed Google Scholar
Vrouenraets BC et al. (2001) Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor-α versus toxicity after melphalan alone. Eur J Surg Oncol27: 390–395 CASPubMed Google Scholar
Eggermont AM (1996) Treatment of melanoma in-transit metastases confined to the limb. Cancer Surv26: 335–349 CASPubMed Google Scholar
Lejeune FJ et al. (1994) Rationale for using TNF alpha and chemotherapy in regional therapy of melanoma. J Cell Biochem56: 52–61 CASPubMed Google Scholar
Lienard D et al. (1999) Isolated limb perfusion with tumour necrosis factor-α and melphalan with or without interferon-γ for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res9: 491–502 CASPubMed Google Scholar
Grünhagen DJ et al. (2004) One hundred consecutive isolated limb perfusions with TNF-α and melphalan in melanoma patients with multiple in-transit metastases. Ann Surg240: 939–947 PubMedPubMed Central Google Scholar
Fraker DL et al. (2002) A phase III trial of isolated limb perfusion for extremity melanoma comparing melphalan alone versus melphalan plus tumor necrosis factor (TNF) plus interferon gamma (IFN). Ann Surg Oncol9 (Suppl): S8 Google Scholar
Rossi CR et al. (2004) Hyperthermic isolated limb perfusion with low-dose tumor necrosis factor-α and melphalan for bulky in-transit melanoma metastases. Ann Surg Oncol11: 173–177 PubMed Google Scholar
Grünhagen DJ et al. (2005) Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure. Ann Surg Oncol12: 609–615 PubMed Google Scholar
Olieman AF et al. (1999) Hyperthermic isolated limb perfusion with tumor necrosis factor alpha, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities: a multicenter study. Arch Surg134: 303–307 CASPubMed Google Scholar
Bickels J et al. (1999) Isolated limb perfusion with tumour necrosis factor-alpha and melphalan for unresectable bone sarcomas of the lower extremity. Eur J Surg Oncol25: 509–514 CASPubMed Google Scholar
Sijens PE et al. (1995) 31P magnetic resonance spectroscopy as predictor for clinical response in human extremity sarcomas treated by single dose TNF-α + melphalan isolated limb perfusion. NMR Biomed18: 215–224 Google Scholar
Rüegg C et al. (1998) Evidence for the involvement of endothelial cell integrin αVβ3 in the disruption of the tumor vasculature induced by TNF and IFN-γ. Nat Med4: 408–414 PubMed Google Scholar
Renard N et al. (1994) Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (TNFα). Int J Cancer57: 656–663 CASPubMed Google Scholar
Nooijen PTGA et al. (1998) Complete response of melanoma in-transit metastasis after isolated limb perfusion with tumor necrosis factor-α and melphalan without massive tumor necrosis: clinical and histopathological study of the delayed-type reaction patterns. Cancer Res58: 4880–4887 CASPubMed Google Scholar
Kristensen CA et al. (1996) Reduction of interstitial fluid pressure after TNF-α treatment of three human melanoma xenografts. Br J Cancer74: 533–536 CASPubMedPubMed Central Google Scholar
de Wilt JH et al. (2000) Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer82: 1000–1003 CASPubMedPubMed Central Google Scholar
van der Veen AH et al. (2000) TNF-alpha augments intratumoural concentration of doxorubicin in TNF-α-based isolated limb perfusion in rat sarcoma models and enhances antitumour effects. Br J Cancer82: 973–980 CASPubMedPubMed Central Google Scholar
van Etten B et al. (2003) Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-based isolated hepatic perfusion. Br J Cancer87: 314–319 Google Scholar
Seynhaeve ALB et al. (2002) Isolated limb perfusion with actinomycin D and TNF-α results in improved tumour response in soft-tissue sarcoma-bearing rats but is accompanied by severe local toxicity. Br J Cancer86: 1174–1179 CASPubMedPubMed Central Google Scholar
Brunstein F et al. (2004) Synergistic antitumor activity of histamine plus melphalan in isolated limb perfusion: preclinical studies. J Natl Cancer Inst96: 1603–1610 CASPubMed Google Scholar
Hoving S et al. (2005) Synergistic antitumor response of interleukin 2 with melphalan in isolated limb perfusion in soft tissue sarcoma-bearing rats. Cancer Res65: 4300–4308 CASPubMed Google Scholar
ten Hagen TL et al. (2000) Low-dose tumor necrosis factor-α augments antitumor activity of stealth liposomal doxorubicin (DOXIL®) in soft tissue sarcoma-bearing rats. Int J Cancer87: 829–837 CASPubMed Google Scholar
Brouckaert P et al. (2004) Tumor necrosis factor-α augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (Doxil®) correlates with altered Doxil® pharmacokinetics. Int J Cancer109: 442–448 CASPubMed Google Scholar
ten Hagen TL and Eggermont AM (2001) TNF is here to stay—revisited. Trends Immunol22: 127–129 CASPubMed Google Scholar